Dr. Mostafa Hamed
Über
Dr. Mostafa Hamed ist Postdoktorand am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) in der Abteilung Wirkstoffdesign und Optimierung. Dr. Hamed arbeitet auf dem Gebiet der medizinischen Chemie mit dem Schwerpunkt im Design und der Optimierung von neuartigen Antiinfektiva und Virulenz-attenuierenden Verbindungen.
Dr. Hamed studierte Pharmazie an der Misr Universität für Wissenschaft und Technologie in Ägypten und erwarb seinen Master in medizinischer Chemie an der Universität Kairo. Im Jahre 2013 promovierte er in medizinischer Chemie an der Universität des Saarlandes.
2024
Hit optimization by dynamic combinatorial chemistry on Streptococcus pneumoniae energy-coupling factor transporter ECF-PanT
Exapicheidou I, Shams A, Ibrahim H, Tsarenko A, Backenköhler M, Hamed M, Diamanti E, Volkamer A, slotboom d, Hirsch A (2024)
Chem. Commun. 60 (7): 870-873DOI: 10.1039/D3CC04738E
Development and evaluation of 2,4-disubstituted-5-aryl pyrimidine derivatives as antibacterial agents
Khalifa H, Rasheed S, Haupenthal J, Herrmann J, Mandour Y, Abadi A, Engel M, Müller R, Hirsch A, Abdel-Halim M, Hamed M (2024)
Archiv der PharmazieDOI: 10.1002/ardp.202300656
2023
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle
Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)
Adv. Sci. (Online)DOI: 10.1002/advs.202204443
2022
Design, Synthesis, Antimicrobial Activity, and Molecular Docking of Some New Diclofenac Derivatives
Tolba M, Hamed M, Sayed M, Kamal El-Dean A, Abdel-Mohsen S, Ibrahim O, Elgaher W, Hirsch A, Saddik A (2022)
Polycyclic Aromatic Compounds: 1-16DOI: 10.1080/10406638.2022.2102661
Structure-Guided Optimization of Small-Molecule Folate Uptake Inhibitors Targeting the Energy-Coupling Factor Transporters
Kiefer A, Bousis S, Hamed M, Diamanti E, Haupenthal J, Hirsch A (2022)
J. Med. Chem.DOI: 10.1021/acs.jmedchem.1c02114
Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors
Hamdy J, Emadeldin N, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2022)
Pharmaceuticals 15 (5)DOI: 10.3390/ph15050632
Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part
Megahed S, Rasheed S, Herrmann J, El-Hossary E, El-Shabrawy Y, Abadi A, Engel M, Müller R, Abdel-Halim M, Hamed M (2022)
Bioorg Med Chem Lett 59DOI: 10.1016/j.bmcl.2022.128531
2021
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Targeting the IspD Enzyme in the MEP Pathway: Identification of a Novel Fragment Class
Diamanti E, Hamed M, Lacour A, Bravo P, Illarionov B, Fischer M, Rottmann M, Witschel M, Hirsch A (2021)
ChemMedChemDOI: 10.1002/cmdc.202100679
Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier
Abdallah M, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2021)
European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2021.114034
Expanding the Myxochelin Natural Product Family by Nicotinic Acid Containing Congeners
Frank N, Széles M, Akone S, Rasheed S, Hüttel S, Frewert S, Hamed M, Herrmann J, Schuler S, Hirsch A, Müller R (2021)
Molecules 26 (16)DOI: 10.3390/molecules26164929
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369
2020
Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics
Elgaher W, Hamed M, Baumann S, Herrmann J, Siebenbürger L, Krull J, Cirnski K, Kirschning A, Brönstrup M, Müller R, Hartmann R (2020)
Chem. Eur. J. 26 (32): 7219-7225DOI: 10.1002/chem.202000117
Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy
Testolin G, Cirnski K, Rox K, Prochnow H, Fetz V, Grandclaudon C, Mollner T, Baiyoumy A, Ritter A, Leitner C, …, Müller R, Brönstrup M (2020)
Chemical Science 11 (5): 1316-1334DOI: 10.1039/C9SC04769G
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)
Patent (EP20150119)
2015
Novel PqsR Inverse Agonists
Hamed M (2015)
Patent (EP 201523196)
Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp
Moreno M, Elgaher W, Herrmann J, Schläger N, Hamed M, Baumann S, Müller R, Hartmann R, Kirschning A (2015)
Synlett 26 (9): 1175-1178DOI: 10.1055/s-0034-1380509